906 Views

AstraZeneca 

“Market Cap $82.32 B As of May 2014

At a Glance
  • Industry: Pharmaceuticals
  • Founded: 1992
  • Country: United Kingdom
  • CEO: Pascal Soriot
  • Website: www.astrazeneca.com
  • Employees: 51,500
  • Sales: $25.69 B
  • Headquarters: London
Forbes Lists

#183 Global 2000

  • #364 in Sales
  • #247 in Profit
  • #427 in Assets
  • #100 in Market value
Profile

AstraZeneca Plc is a global research-based biopharmaceutical company, which primarily focuses on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. The company sells products under the brands Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on April 6, 1999 and is headquartered in London, the United Kingdom.

AstraZeneca History

AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK – two companies with similar science-based cultures and a shared vision of the pharmaceutical industry.

The merger aimed to improve the combined companies’ ability to deliver long term growth and enduring shareholder value through:

Global power & reach in sales and marketing

  • Ability to deliver the potential of existing and future products through the power and reach of a combined global sales and marketing resource
  • Widespread class coverage in key therapy areas, such as cardiovascular and respiratory disease, due to complementary nature of products
  • Major primary care presence, particularly in gastrointestinal, cardiovascular and respiratory medicine
  • Leading position in a number of specialist/hospital markets, including oncology and anaesthesia

Stronger R&D platform for innovation-led growth

  • Substantial research and development (R&D) expenditure
  • Strong combined development pipeline
  • Potential for further strengthening of the pipeline by enhanced discovery and development capability through greater scale and focus on selected areas and technologies

Greater financial strategic flexibility

  • Financial strength and scale to give AstraZeneca’s management greater strategic flexibility to drive long-term earnings growth
  • Substantial operational efficiencies resulting in cost savings.”

*Information from Forbes.com and Astrazeneca.com

**Video published on YouTube by “AstraZeneca